Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 742-749

  Acikalin, Mustafa Fuat ^a,b   Etiz, Durmus ^a   Gurbuz, Melek Kezban ^a   Ozudogru, Erkan ^a   Canaz, Funda ^a   Colak, Ertugrul ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Gültepe Mah Üniversite Evleri   (Turkey)

Author keywords

Cyclin D1; Galectin 3; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

CYCLIN D1; GALECTIN 3; CCND1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISTANT METASTASIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNDIFFERENTIATED CARCINOMA; ADOLESCENT; AGED; CANCER STAGING; CARCINOMA; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CYCLIN D1; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84866276661     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9971-3     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Xu L, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Radiother Oncol. 2010;96:94-9.
3. Liu MT, et al. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003;33:501-8.
4. Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H. Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg. 2006;134:639-45.
5. Nakamura T, et al. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol. 2008;38:803-9.
6. Ho HC, et al. Prognostic influence of parapharyngeal extension in nasopharyngeal carcinoma. Acta Otolaryngol. 2008;128:790-8.
7. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269:20807-10.
8. Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305-28.
9. Nangia-Makker P, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000;156:899-909.
10. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 2001;7:661-8.
11. Raz A, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer. 1990;46: 871-7.
12. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272-6.
13. Sakaki M, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest. 2010;57:152-7.
14. Honjo Y, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6: 4635-40.
15. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815-22.
16. Wang Y, et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol. 2009;174:1515-23.
17. Castronovo V, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996; 179:43-8.
18. van den Brule FA, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996;27:1185-91.
19. Piantelli M, et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol. 2002;20:3850-6.
20. Plzák J, et al. Galectin-3-an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer. 2004;40: 2324-30.
21. Wu CC, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomic. 2005;5:3173-82.
22. Chou J, et al. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck. 2008;30:946-63.
23. Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73:1059-65.
24. Michalides RJ, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997;123:497-502.
25. Ayhan S, et al. The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology. 2010;57:251-6.
26. Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res. 2004;10:6598-605.
27. Yurakh AO, et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol. 2006;50:506-15.
28. Michalides R, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995;55:975-8.
29. Hwang CF, et al. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol. 2002;13:1246-51.
30. Lai JP, et al. Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope. 2002;112:402-8.
31. Lin HS, Berry GJ, Sun Z, Fee WE Jr. Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma. World J Surg Oncol. 2006;4:62.
32. Fu ZJ, et al. Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. Clin Exp Metastasis. 2008; 25:887-92.
33. Shimura T, et al. Galectin-3, a novel binding partner of b-catenin. Cancer Res. 2004;64:6363-7.
34. Weinberger PM, et al. Association of nuclear, cytoplasmic expression of galectin-3 with b-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007; 133:503-10.
35. Lin HM, Pestell RG, Raz A, Kim HRC. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 2002;21: 8001-10.
36. Ferrazzo KL, Neto MM, dos Santos E, dos Santos Pinto D, de Sousa SO. Differential expression of galectin-3, b-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous lowgrade adenocarcinoma of salivary gland. J Oral Pathol Med. 2009; 38:701-7.